PT  - JOURNAL ARTICLE
AU  - Lynne M. Howells
AU  - Jagdish Mahale
AU  - Stewart Sale
AU  - Laura McVeigh
AU  - William P. Steward
AU  - Anne Thomas
AU  - Karen Brown
TI  - Translating Curcumin to the Clinic for Lung Cancer Prevention: Evaluation of the Preclinical Evidence for Its Utility in Primary, Secondary, and Tertiary Prevention Strategies
AID  - 10.1124/jpet.114.216333
DP  - 2014 Sep 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 483--494
VI  - 350
IP  - 3
4099  - http://jpet.aspetjournals.org/content/350/3/483.short
4100  - http://jpet.aspetjournals.org/content/350/3/483.full
SO  - J Pharmacol Exp Ther2014 Sep 01; 350
AB  - Lung cancer is responsible for over one million deaths worldwide each year. Smoking cessation for lung cancer prevention remains key, but it is increasingly acknowledged that prevention strategies also need to focus on high-risk groups, including ex-smokers, and patients who have undergone resection of a primary tumor. Models for chemoprevention of lung cancer often present conflicting results, making rational design of lung cancer chemoprevention trials challenging. There has been much focus on use of dietary bioactive compounds in lung cancer prevention strategies, primarily due to their favorable toxicity profile and long history of use within the human populace. One such compound is curcumin, derived from the spice turmeric. This review summarizes and stratifies preclinical evidence for chemopreventive efficacy of curcumin in models of lung cancer, and adjudges the weight of evidence for use of curcumin in lung cancer chemoprevention strategies.